摘要
年龄相关性黄斑变性（AMD）是一种慢性、进展性视力损害性疾病。近年来湿性AMD治疗方面取得巨大进展，接受眼内注射抗血管内皮生长因子A（VEGF—A）治疗的湿性AMD患者数量迅速增加，并在短期内能够有效控制病情。改善视力。随着治疗和随访周期的延长，抗VEGF-A类药物治疗湿性AMD的长期疗效成为患者和医生关注的焦点。本文将概述治疗湿性AMD的常用抗VEGF-A类药物，并对其长期疗效及安全性进行总结，探讨分析长期应用抗VEGF—A类药物影响视力预后的原因。
As a progressive chronic disease, age-related macular degeneration （AMD） is the leading cause of blindness worldwide. However,current therapy for AMD shows a dramatic breakthrough. More and more patients with AMD undergo intravitreous injection of anti-vascular endothelial growth factor A （VEGF-A） regimen,which has been demonstrated a beneficial therapeutic treatment to improve visual acuity in a short period. The long-term outcomes have come into focus considering prolonged treatment cycle and follow-up period. The long-term outcomes and safety of anti VEGF-A will be reviewed in this article contributing to investigate the causes influencing prognosis of visual acuity after anti VEGF-A treatment.
作者
杨仕琪
孙晓东
Yang Shiqi,Sun Xiaodong(Department of Ophthalmology, Shanghai First People＇s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, Chin)
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2018年第3期236-240,共5页
Chinese Journal Of Experimental Ophthalmology
基金
国家自然科学基金重点项目（81730026）
关键词
年龄相关性黄斑变性/湿性
脉络膜新生血管
血管内皮生长因子
长期疗效
Age-related macular degeneration, wet
Choroidal neovascularization
Vascular endothelialgrowth factor
Long-term outcomes
